Astrazeneca (AZN) Retained Earnings (2016 - 2026)

Astrazeneca has reported Retained Earnings over the past 17 years, most recently at $9.7 billion for Q1 2026.

For Q1 2026, Retained Earnings rose 187.51% year-over-year to $9.7 billion; the TTM value through Mar 2026 reached $9.7 billion, up 187.51%, while the annual FY2025 figure was $11.0 billion, 247.22% up from the prior year.
Retained Earnings for Q1 2026 was $9.7 billion at Astrazeneca, down from $11.0 billion in the prior quarter.
Over five years, Retained Earnings peaked at $11.0 billion in Q4 2025 and troughed at -$2.5 billion in Q3 2022.
A 5-year average of $2.4 billion and a median of $1.5 billion in 2023 define the central range for Retained Earnings.
Biggest five-year swings in Retained Earnings: plummeted 212.32% in 2022 and later soared 1686.79% in 2025.
Year by year, Retained Earnings stood at -$574.0 million in 2022, then soared by 361.67% to $1.5 billion in 2023, then surged by 110.39% to $3.2 billion in 2024, then surged by 247.22% to $11.0 billion in 2025, then decreased by 11.85% to $9.7 billion in 2026.
Business Quant data shows Retained Earnings for AZN at $9.7 billion in Q1 2026, $11.0 billion in Q4 2025, and $8.2 billion in Q3 2025.

Peer Comparison